DK3068403T3 - Fremgangsmåder til behandling af øjentilstande med et implantat med langvarig lægemiddelfrigivelse - Google Patents

Fremgangsmåder til behandling af øjentilstande med et implantat med langvarig lægemiddelfrigivelse Download PDF

Info

Publication number
DK3068403T3
DK3068403T3 DK14805768.0T DK14805768T DK3068403T3 DK 3068403 T3 DK3068403 T3 DK 3068403T3 DK 14805768 T DK14805768 T DK 14805768T DK 3068403 T3 DK3068403 T3 DK 3068403T3
Authority
DK
Denmark
Prior art keywords
procedures
treatment
long
drug release
release implant
Prior art date
Application number
DK14805768.0T
Other languages
Danish (da)
English (en)
Inventor
Jane-Guo Shiah
Rahul Bhagat
Wendy M Blanda
Thierry Nivaggioli
Lin Peng
David Chou
David A Weber
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52001114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3068403(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK3068403T3 publication Critical patent/DK3068403T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts or implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
DK14805768.0T 2013-11-15 2014-11-14 Fremgangsmåder til behandling af øjentilstande med et implantat med langvarig lægemiddelfrigivelse DK3068403T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904887P 2013-11-15 2013-11-15
PCT/US2014/065804 WO2015073895A1 (en) 2013-11-15 2014-11-14 Methods of treatment of ocular conditions with a sustained drug delivery implant

Publications (1)

Publication Number Publication Date
DK3068403T3 true DK3068403T3 (da) 2020-09-07

Family

ID=52001114

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14805768.0T DK3068403T3 (da) 2013-11-15 2014-11-14 Fremgangsmåder til behandling af øjentilstande med et implantat med langvarig lægemiddelfrigivelse

Country Status (24)

Country Link
US (2) US20150140062A1 (https=)
EP (2) EP3714875A1 (https=)
JP (2) JP6675307B2 (https=)
KR (3) KR20240058976A (https=)
CN (1) CN105764517A (https=)
AU (4) AU2014348369B2 (https=)
CA (1) CA2929689A1 (https=)
CL (1) CL2016001167A1 (https=)
CY (1) CY1123344T1 (https=)
DK (1) DK3068403T3 (https=)
ES (1) ES2819215T5 (https=)
HU (1) HUE050913T2 (https=)
IL (2) IL245548A0 (https=)
MX (2) MX2016006334A (https=)
MY (1) MY176039A (https=)
NZ (1) NZ719953A (https=)
PH (1) PH12016500869A1 (https=)
PL (1) PL3068403T3 (https=)
PT (1) PT3068403T (https=)
RU (1) RU2690841C1 (https=)
SG (1) SG10201809363SA (https=)
SI (1) SI3068403T1 (https=)
UA (1) UA122117C2 (https=)
WO (1) WO2015073895A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3324944A4 (en) * 2015-07-23 2019-04-03 Aerie Pharmaceuticals, Inc. INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE
JP2019534063A (ja) 2016-09-02 2019-11-28 エンビシャ セラピューティクス インコーポレイテッド インプラントアプリケータ
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
CA3174217A1 (en) * 2020-07-16 2022-01-20 Ocular Therapeutix, Inc. Ocular insert containing a glucocorticoid
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU2002236495B2 (en) 2000-11-29 2006-05-11 Allergan, Inc. Intraocular implants for preventing transplant rejection in the eye
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
CN103402582A (zh) * 2011-02-11 2013-11-20 普西维达公司 使用抗水肿疗法治疗黄斑水肿的方法

Also Published As

Publication number Publication date
AU2024205640A1 (en) 2024-08-29
US20250319031A1 (en) 2025-10-16
AU2020204362A1 (en) 2020-07-23
NZ719953A (en) 2022-01-28
RU2016119132A (ru) 2017-12-20
ES2819215T3 (es) 2021-04-15
AU2014348369B2 (en) 2020-04-02
MY176039A (en) 2020-07-22
CY1123344T1 (el) 2021-12-31
RU2690841C1 (ru) 2019-06-06
SI3068403T1 (sl) 2020-11-30
MX2016006334A (es) 2016-09-06
ES2819215T5 (en) 2026-04-01
MX2022002306A (es) 2022-03-25
EP3714875A1 (en) 2020-09-30
EP3068403B1 (en) 2020-06-17
EP3068403B2 (en) 2025-12-03
JP2016538292A (ja) 2016-12-08
HUE050913T2 (hu) 2021-01-28
SG10201809363SA (en) 2018-11-29
JP6675307B2 (ja) 2020-04-01
UA122117C2 (uk) 2020-09-25
KR20160085847A (ko) 2016-07-18
PH12016500869B1 (en) 2016-07-04
US20150140062A1 (en) 2015-05-21
WO2015073895A1 (en) 2015-05-21
KR20220082934A (ko) 2022-06-17
CL2016001167A1 (es) 2017-01-06
CA2929689A1 (en) 2015-05-21
KR102475746B1 (ko) 2022-12-08
JP2020055862A (ja) 2020-04-09
CN105764517A (zh) 2016-07-13
KR20240058976A (ko) 2024-05-07
PH12016500869A1 (en) 2016-07-04
IL290837A (en) 2022-04-01
AU2024205640B2 (en) 2025-10-23
EP3068403A1 (en) 2016-09-21
PL3068403T3 (pl) 2021-01-11
AU2022204607A1 (en) 2022-07-21
PT3068403T (pt) 2020-09-18
JP7022735B2 (ja) 2022-02-18
IL245548A0 (en) 2016-06-30
AU2014348369A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
DK2911623T3 (da) Oftalmisk system til langvarig frigivelse af lægemiddel til øjet
DK3068403T3 (da) Fremgangsmåder til behandling af øjentilstande med et implantat med langvarig lægemiddelfrigivelse
DK3329884T3 (da) Implanterbar indretning til behandling af glaukom
DK2989574T3 (da) Behandlingsapparat med aktivering af medicinsk funktion
DK3230909T3 (da) Parring af et medicinsk apparat med en styreenhed
DK3351239T3 (da) Prostamid-indeholdende intraokulære implantater og fremgangsmåder til anvendelse deraf
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK3003309T3 (da) Behandling af cancer med PI3-kinase-isoform modulatorer
DK3191020T3 (da) Medicinsk/kirurgisk implantat
DK3041926T3 (da) Indretning til in-vitro-modellering af in-vivo-væv af organer
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
DK2968880T3 (da) Lægemiddelafgivelsesindretninger med lægemiddelpermeabel komponent
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3035926T3 (da) Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
DK2999418T3 (da) Fremgangsmåde til fremstilling af en kirurgisk guide til knoglehøst
EP3878404C0 (en) ARTIFICIAL VASCULAR GRAFT
DK3023100T3 (da) Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer
DK3007726T3 (da) Fremgangsmåder til behandling af en tauopati
DK2953904T3 (da) Fremgangsmåde til kontrolleret fremstilling af et biocid
DK2818241T3 (da) Fremgangsmåde til fremstilling af behandlingsapparat udstyret med katalysatorbærende honeycombstruktur
DK3193978T3 (da) Lægemiddelinjektor af hudplastertypen til voluminøs bolus med medikamentforvarmning
DK3065761T3 (da) Fremgangsmåde til behandling af tilstande af øjet med en anti-vegf darpin
DK3280470T3 (da) Medicinsk injektionsindretning med en kappe
DK2968146T3 (da) Liposomsammensætning med kontrolleret lægemiddelfrigivelse
EP3005981A4 (en) IMPLANTABLE LENS FOR CORRECTION OF SHORT-TERM AND MANUFACTURING METHOD THEREFOR